[ 18 F]Fluoromisonidazole PET in rectal cancer

Tanuj Puri; Tessa A. Greenhalgh; James M. Wilson; Jamie Franklin; Lia Mun Wang; Victoria Strauss; Chris Cunningham; Mike Partridge; Tim Maughan

doi:10.1186/s13550-017-0324-x

EJNMMI Research

Table 2 Tumour:Muscle (T:M) SUVmax ratio and hypoxic volume at baseline and after 8–10 fractions of CRT from [¹⁸F]FMISO PET scans at 4 h

From: [¹⁸F]Fluoromisonidazole PET in rectal cancer

				Baseline						After 8–10# CRT						% Change
Patient	pTRG	Stage	Clinical	Tumour	Muscle	T:M	Tumour	Tumour	% of	Tumour	Muscle	T:M	Tumour	Tumour	% of	Tumour	Muscle	T:M	Tumour	Tumour	% of
Number	AJCC		Response	SUV	SUV	SUV	hypoxic	ROI	tumour	SUV	SUV	SUV	hypoxic	ROI	tumour	SUV	SUV	SUV	hypoxic	ROI	tumour
				max	max	max	volume	volume	volume	max	max	max	volume	volume	volume	max	max	max	volume	volume	volume
							cm³	cm³	i.e. hypoxic				cm³	cm³	i.e. hypoxic						i.e. hypoxic
P1	1	ypT3N2	Poor	2.09	1.54	1.35	0.05	80.41	0.06	1.79	1.32	1.36	0.15	88.60	0.17	−14.35	−14.50	0.17	199.99	10.19	172.26
P2	1	ypT3N1	Good	5.19	2.30	2.26	1.93	23.20	8.32	4.97	1.73	2.87	2.93	26.85	10.93	−4.31	−24.68	27.05	51.90	15.70	31.28
P3	3	ypT3N0	Poor	3.39	1.95	1.74	0.98	179.77	0.54	2.24	1.93	1.16	0.00	86.53	0.00	−33.86	−1.00	−33.19	−100.00	−51.87	−100.00
P4	2	ypT3N0	Poor	4.16	1.74	2.39	4.03	30.66	13.16	2.70	1.84	1.47	0.20	13.35	1.47	−35.10	5.79	−38.65	−95.15	−56.46	−88.86
P5	NR	N/A	Good	4.98	1.93	2.58	3.18	62.59	5.08	1.78	1.68	1.06	0.00	55.79	0.00	−64.17	−12.69	−58.96	−100.00	−10.86	−100.00
P6	NR	N/A	Poor	3.38	2.03	1.66	0.81	18.80	4.29	-	-	-	-	-	-	-	-	-	-	-	-
P7	NR	N/A	Good	3.52	1.62	2.17	0.39	4.16	9.41	2.44	1.51	1.62	0.12	0.93	13.16	−30.54	−6.85	−25.43	−68.75	−77.65	39.80
P8	2	ypT3N2	Poor	5.31	2.35	2.27	1.17	28.43	4.13	2.49	1.95	1.27	0.00	28.61	0.00	−53.22	−16.71	−43.84	−100.00	0.60	−100.00
P9	2	ypT3N1	Poor	3.04	1.45	2.10	1.44	15.06	9.58	1.82	1.41	1.30	0.00	13.96	0.00	−39.97	−2.59	−38.37	−100.00	−7.31	−100.00
P10	0	ypT0N1	Good	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
P11	2	ypT3N0	Good^*	1.94	1.74	1.11	0.00	10.98	0.00	2.40	1.88	1.27	0.00	5.23	0.00	23.87	8.16	14.52	0.00	−52.34	0.00
Median				3.46	1.83	2.14	1.08	25.82	4.68	2.40	1.73	1.30	0.00	26.85	0.00	−33.86	−6.85	−33.19	−95.15	−10.86	−88.86
IQR				1.65	0.36	0.58	1.31	38.61	7.70	0.66	0.37	0.19	0.15	42.44	1.47	25.62	13.49	38.81	100.00	52.94	131.28

Response as defined in Table 1
[ ¹⁸ F]FMISO [¹⁸F]fluoromisonidazole, PET positron emission tomography, SUV standardised uptake value, T:M tumour to muscle ratio, max maximum, % percentage, CRT chemoradiotherapy, IQR interquartile range, i.e. that is, ROI region of interest, NR No resection, N/A not applicable, cm ³ cubic centimetre, h hour, ^*Delayed surgery due to initial good response, clinical outcome used; TRG tumour regression grade, AJCC American Joint Committee on Cancer

Back to article page